A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172

Status	RECRUITING
Phase	Phase 1
Sponsor	CRISPR Therapeutics AG
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (6)

- Age of e18 and d75 years at the time of signing the informed consent.
- Able to provide written informed consent.
- Participants diagnosed with persistent dyslipidemias defined by TG e150 mg/dL - and LDL-C e70 mg/dL in participants with ASCVD, or LDL-C e70 or 100mg/dL in participants with or without ASCVD respectively, or TG e500 mg/dL.
- Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening
- Female participants must be postmenopausal or surgically sterile.

... and 1 more (see full listing online)

Exclusion (9)

- Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.
- Evidence of liver disease, defined as but not limited to:
- LFTS \>2 × upper limit of normal (ULN), or total bilirubin \>2 × ULN, or INR \>1.5 × ULN, or liver stiffness measured by liver elastography
- Abnormal or compromised function of kidney, heart, blood or liver.
- Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.

... and 4 more (see full listing online)

Locations (18 total)

Research Site 10, Jacksonville, Florida, United States
Research Site 17, Orlando, Florida, United States
Research Site 11, Port Orange, Florida, United States
... and 15 more locations